التفاصيل البيبلوغرافية
| العنوان: |
Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues. |
| المؤلفون: |
Gautier, J.F.1, Monguillon, P.2, Verier-Mine, O.3, Valensi, P.4, Fiquet, B.5 beatrice.fiquet@novartis.com, Dejager, S.6, Charbonnel, B.7 |
| المصدر: |
Diabetes Research & Clinical Practice. Jun2016, Vol. 116, p26-28. 3p. |
| مصطلحات موضوعية: |
*ORAL medicine, *HYPOGLYCEMIC agents, *COMBINATION drug therapy, *HYPOGLYCEMIA treatment, *PEOPLE with diabetes, *RANDOMIZED controlled trials, *THERAPEUTIC use of protease inhibitors, *INSULIN therapy, *PILOT projects, *GLYCOSYLATED hemoglobin, *RESEARCH, *INSULIN secretagogues, *HETEROCYCLIC compounds, *RESEARCH methodology, *SULFONYLUREAS, *ORGANIC compounds, *BLOOD sugar, *EVALUATION research, *TYPE 2 diabetes, *HYDROCARBONS, *COMPARATIVE studies, *HYPOGLYCEMIA, *METFORMIN |
| مستخلص: |
We conducted a pilot study to evaluate two therapeutic strategies at the time of insulin initiation in type 2 diabetic patients insufficiently controlled with metformin+insulin-secretagogues (IS, sulfonylureas or glinides). Patients were randomized to remain under the same dual therapy or to receive metformin+DPP4 inhibitors while starting insulin. Similar glycemic control was achieved in both groups. However less hypoglycemia was observed with DPP4 inhibitors despite higher doses of insulin. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
